Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 448
Filter
1.
Front Endocrinol (Lausanne) ; 15: 1435102, 2024.
Article in English | MEDLINE | ID: mdl-39359414

ABSTRACT

Background: It is challenging for clinicians to distinguish adrenocortical carcinoma (ACC) from benign adrenocortical adenomas (ACA) in their early stages. This study explored the value of serum steroid profiling as a complementary biomarker for malignancy diagnosis of ACC other than diameter and explored the influence of sex and functional status. Methods: In this retrospective study, a matched cohort of patients diagnosed with either ACC or ACA based on histopathology was meticulously paired in a 1:1 ratio according to sex, age, and functional status. Eight serum steroids including 11-deoxycortisol, 11-deoxycorticosterone, progesterone, androstenedione, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), 17-hydroxyprogesterone, and estradiol, were quantified by liquid chromatography tandem mass spectrometry. We conducted a comparative analysis of the clinical characteristics and serum steroid profiles of patients with ACC and ACA, with further subgroup analysis. Results: The study included 31 patients with ACC and 31 matched patients with ACA. Patients with ACC exhibited significantly larger tumor diameters, lower body mass index (BMI), and higher levels of 11-deoxycortisol, progesterone, and androstenedione than those with ACA. 11-deoxycortisol was the only valuable index for discriminating ACC from ACA, regardless of functional status and sex. Progesterone, DHEA, and DHEAS levels were higher in the functional ACC group than in the non-functional ACC group. Female ACC patients, especially in postmenopausal female exhibited higher levels of androstenedione than male patients. The area under the curve of tumor diameter, 11-deoxycortisol, and BMI was 0.947 (95% CI 0.889-1.000), with a sensitivity of 96.8% and specificity of 90.3%. Conclusion: Serum steroid profiling serves as a helpful discriminative marker for ACC and ACA, with 11-deoxycortisol being the most valuable marker. For other steroid hormones, consideration of sex differences and functional status is crucial.


Subject(s)
Adrenal Cortex Neoplasms , Adrenocortical Adenoma , Adrenocortical Carcinoma , Humans , Male , Female , Adrenal Cortex Neoplasms/blood , Adrenal Cortex Neoplasms/diagnosis , Adrenal Cortex Neoplasms/pathology , Adrenocortical Carcinoma/blood , Adrenocortical Carcinoma/diagnosis , Middle Aged , Retrospective Studies , Adrenocortical Adenoma/blood , Adrenocortical Adenoma/diagnosis , Adrenocortical Adenoma/pathology , Adult , Steroids/blood , Diagnosis, Differential , Aged , Biomarkers, Tumor/blood , Sex Factors
2.
Int J Mol Sci ; 25(16)2024 Aug 09.
Article in English | MEDLINE | ID: mdl-39201408

ABSTRACT

Adrenal tumors, such as adrenocortical carcinoma (ACC), adrenocortical adenoma (ACA), and pheochromocytoma (PCC) are complex diseases with unclear causes and treatments. Mitochondria and mitochondrial-derived peptides (MDPs) are crucial for cancer cell survival. The primary aim of this study was to analyze samples from different adrenal diseases, adrenocortical carcinoma, adrenocortical adenoma, and pheochromocytoma, and compare them with normal adrenal tissue to determine whether the expression levels of the mitochondrial open reading frame of the 12S rRNA type-c (MOTS-c) gene and protein vary between different types of adrenal tumors compared to healthy controls using qPCR, ELISA, and IHC methods. Results showed decreased MOTS-c mRNA expression in all adrenal tumors compared to controls, while serum MOTS-c protein levels increased in ACA and PCC but not in ACC. The local distribution of MOTS-c protein in adrenal tissue was reduced in all tumors. Notably, MOTS-c protein expression declined with ACC progression (stages III and IV) but was unrelated to patient age or sex. Tumor size and testosterone levels positively correlated with MOTS-c mRNA but negatively with serum MOTS-c protein. Additionally, serum MOTS-c protein correlated positively with glucose, total cholesterol, HDL, LDL, and SHGB levels. These findings suggest disrupted expression of MOTS-c in the spectrum of adrenal diseases, which might be caused by mechanisms involving increased mitochondrial dysfunction and structural changes in the tissue associated with disease progression. This study provides a detailed examination of MOTS-c mRNA and protein in adrenal tumors, indicating the potential role of MDPs in tumor biology and progression.


Subject(s)
Adrenal Gland Neoplasms , Pheochromocytoma , Humans , Male , Female , Middle Aged , Adrenal Gland Neoplasms/genetics , Adrenal Gland Neoplasms/metabolism , Adrenal Gland Neoplasms/pathology , Adrenal Gland Neoplasms/blood , Adult , Pheochromocytoma/genetics , Pheochromocytoma/metabolism , Pheochromocytoma/pathology , Pheochromocytoma/blood , Mitochondrial Proteins/genetics , Mitochondrial Proteins/metabolism , Gene Expression Regulation, Neoplastic , Aged , Adrenocortical Adenoma/genetics , Adrenocortical Adenoma/metabolism , Adrenocortical Adenoma/pathology , Adrenocortical Adenoma/blood , RNA, Messenger/genetics , RNA, Messenger/metabolism , Adrenocortical Carcinoma/genetics , Adrenocortical Carcinoma/metabolism , Adrenocortical Carcinoma/pathology , Adrenocortical Carcinoma/blood , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Biomarkers, Tumor/blood
3.
BMC Endocr Disord ; 24(1): 116, 2024 Jul 16.
Article in English | MEDLINE | ID: mdl-39010034

ABSTRACT

BACKGROUND: Somatic mutations have been observed to induce aldosterone-producing adenomas (APAs). These may be accelerated during pregnancy. Somatic PRKACA mutations are common in cortisol-producing adenomas (CPAs). However, their role in APAs, particularly aldosterone- and cortisol-producing adenomas (A/CPAs), is not well understood. This study aims to investigate the association between PRKACA mutations and the accelerated development of A/CPAs during pregnancy. CASE PRESENTATION: A patient with primary aldosteronism (PA) associated with severe Cushing's syndrome (CS) underwent surgical resection of an adrenal tumor one year after delivery. Pathologic examination revealed an adrenocortical adenoma characterized primarily by zona glomerulosa hyperplasia. Somatic mutation analysis revealed the presence of the somatic PRKACA mutation, which was validated as a deleterious mutation by various computational databases. Immunohistochemical results showed positive staining for cytochrome P450 family 11 subfamily B member 1 (CYP11B1), cytochrome P450 family 11 subfamily B member 2 (CYP11B2), and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). Our study included a review of 20 previously documented cases of aldosterone- and cortisol-producing adenomas (A/CPAs), two of which were concurrently positive for both CYP11B1 and CYP11B2, consistent with our findings. CONCLUSION: Somatic mutations in PRKACA may correlate with the upregulation of LHCGR, which synergistically drives the accelerated growth of co-secretion tumors during pregnancy, thereby exacerbating disease progression.


Subject(s)
Adrenal Cortex Neoplasms , Adrenocortical Adenoma , Aldosterone , Cyclic AMP-Dependent Protein Kinase Catalytic Subunits , Hydrocortisone , Mutation , Pregnancy Complications, Neoplastic , Humans , Female , Pregnancy , Adult , Hydrocortisone/metabolism , Adrenocortical Adenoma/genetics , Adrenocortical Adenoma/pathology , Adrenocortical Adenoma/metabolism , Adrenocortical Adenoma/surgery , Adrenal Cortex Neoplasms/genetics , Adrenal Cortex Neoplasms/pathology , Adrenal Cortex Neoplasms/metabolism , Aldosterone/metabolism , Cyclic AMP-Dependent Protein Kinase Catalytic Subunits/genetics , Pregnancy Complications, Neoplastic/genetics , Pregnancy Complications, Neoplastic/pathology , Hyperaldosteronism/genetics , Hyperaldosteronism/pathology , Hyperaldosteronism/surgery , Cushing Syndrome/genetics , Cushing Syndrome/pathology , Adenoma/genetics , Adenoma/pathology , Adenoma/metabolism
4.
BMC Endocr Disord ; 24(1): 122, 2024 Jul 24.
Article in English | MEDLINE | ID: mdl-39044264

ABSTRACT

BACKGROUND: Functioning adrenal adenoma during pregnancy is rare, and the diagnosis is challenging owing to unspecific symptoms and restricted investigations. The obstetric outcomes of patients who undergo surgery during pregnancy or who receive only medical treatment are poorly described. OBJECTIVE: The aim was to investigate the associations between functioning adrenal adenomas and obstetric outcomes. METHODS: A retrospective study was performed in a tertiary center over 20 years. The clinical characteristics, management and obstetric outcomes of the diagnosed pregnant women were reviewed. RESULTS: A total of 12 women were diagnosed with functioning adrenal adenomas during pregnancy from January 2002 to September 2022. Eight women had cortisol-secreting adrenal adenomas, two had excessive catecholamine secretion, and two had primary aldosteronism. The initial symptoms of adrenal adenoma during pregnancy included hypertension or preeclampsia, gestational diabetes mellitus or prepregnancy diabetes mellitus, hypokalemia and ecchymosis. Four women underwent adrenalectomy during pregnancy, while 8 women received only medical therapy. Preterm birth occurred in all patients who received medicine, whereas 1 patient who underwent surgery experienced preterm birth. Among the 8 women in the medical treatment group, 3 had neonates who died. CONCLUSIONS: Once hypertension, hyperglycemia and hypokalemia occur during the 1st or 2nd trimester, pregnant women with adrenal adenomas should be evaluated via laboratory and imaging examinations. The maternal and fetal outcomes were unpredictable owing to the severity of adrenal adenoma, particularly in patients who received only medical treatment. Adrenalectomy should be recommended during pregnancy.


Subject(s)
Adrenal Gland Neoplasms , Pregnancy Complications, Neoplastic , Pregnancy Outcome , Tertiary Care Centers , Humans , Female , Pregnancy , Adult , Retrospective Studies , Adrenal Gland Neoplasms/complications , Adrenal Gland Neoplasms/surgery , Adenoma/complications , Adenoma/surgery , Adrenalectomy , Adrenocortical Adenoma/complications , Adrenocortical Adenoma/surgery , Adrenocortical Adenoma/pathology , Prognosis , Young Adult
5.
J Clin Endocrinol Metab ; 109(10): 2433-2443, 2024 Sep 16.
Article in English | MEDLINE | ID: mdl-38888173

ABSTRACT

CONTEXT: The search for somatic mutations in adrenals resected from patients with primary aldosteronism (PA) is performed by Sanger sequencing, often implemented with immunohistochemistry (IHC)-guidance focused on aldosterone-producing (CYP11B2-positive) areas. OBJECTIVE: To investigate the impact of double IHC for CYP11B1 and CYP11B2 on Sanger and next-generation sequencing (NGS). METHODS: We investigated 127 consecutive adrenal aldosterone-producing adenomas from consenting surgically cured PA patients using double IHC for CYP11B1 and CYP11B2, by Sanger sequencing and NGS. RESULTS: Double IHC for CYP11B2 and CYP11B1 revealed 3 distinct patterns: CYP11B2-positive adenoma (pattern 1), mixed CYP11B1/CYP11B2-positive adenoma (pattern 2), and adrenals with multiple small CYP11B2-positive nodules (pattern 3). Sanger sequencing allowed detection of KCNJ5 mutations in 44% of the adrenals; NGS revealed such mutations in 10% of those negative at Sanger and additional mutations in 61% of the cases. Importantly the rate of KCNJ5 mutations differed across patterns: 17.8% in pattern 1, 71.4% in pattern 2, and 10.7% in pattern 3 (χ2 = 22.492, P < .001). CONCLUSION: NGS allowed detection of mutations in many adrenals that tested negative at Sanger sequencing. Moreover, the different distribution of KCNJ5 mutations across IHC patterns indicates that IHC-guided sequencing protocols selecting CYP11B2-positive areas could furnish results that might not be representative of the entire mutational status of the excised adrenal, which is important at a time when KCNJ5 mutations are suggested to drive management of patients with aldosterone-producing adenomas.


Subject(s)
Cytochrome P-450 CYP11B2 , G Protein-Coupled Inwardly-Rectifying Potassium Channels , Hyperaldosteronism , Immunohistochemistry , Mutation , Steroid 11-beta-Hydroxylase , Humans , Hyperaldosteronism/genetics , Hyperaldosteronism/diagnosis , Hyperaldosteronism/metabolism , G Protein-Coupled Inwardly-Rectifying Potassium Channels/genetics , G Protein-Coupled Inwardly-Rectifying Potassium Channels/metabolism , Steroid 11-beta-Hydroxylase/genetics , Steroid 11-beta-Hydroxylase/metabolism , Cytochrome P-450 CYP11B2/genetics , Cytochrome P-450 CYP11B2/metabolism , Female , Male , Middle Aged , Adult , High-Throughput Nucleotide Sequencing , Adrenocortical Adenoma/genetics , Adrenocortical Adenoma/metabolism , Adrenocortical Adenoma/pathology , Adrenocortical Adenoma/diagnosis , Aged , Adrenal Cortex Neoplasms/genetics , Adrenal Cortex Neoplasms/metabolism , Adrenal Cortex Neoplasms/diagnosis , Adrenal Cortex Neoplasms/pathology
6.
Endocr J ; 71(8): 789-797, 2024 Aug 08.
Article in English | MEDLINE | ID: mdl-38945931

ABSTRACT

The aim of this study was to determine the tissue expressions of vascular endothelial growth factor (VEGF) and endocan in adrenal cortical tumors and the factors associated with them. The study included 6 subjects with adrenocortical adenoma (ACA), 7 subjects with adrenocortical carcinoma (ACC), and 13 control subjects with a normal adrenal cortex. The status of VEGF and endocan expression was determined by the proportions of cells staining on a scale ranging from negative (not staining at all) to strongly positive. VEGF expression was detected in 1 (16.7%) of 6 subjects in the ACA group and in 6 (85.7%) of 7 subjects in the ACC group. VEGF expression was not detected in any of the subjects in the control group. Endocan expression was detected in 6 (100%) of 6 subjects in the ACA group and in 7 (100%) of 7 subjects in the ACC group, while it was detected in only 4 (30.7%) of 13 subjects in the control group. VEGF was expressed with a high frequency in subjects with ACC and with a low frequency in subjects with ACA, but it was not expressed in subjects with normal adrenal cortex tissue. Although endocan was expressed with a higher frequency in subjects with ACC and ACA, it was also expressed in subjects with normal adrenal cortex tissue. The percentage of cells expressed endocan in subjects with ACC was also significantly higher than in subjects with both ACA and normal adrenal cortex.


Subject(s)
Adrenal Cortex Neoplasms , Adrenocortical Adenoma , Adrenocortical Carcinoma , Neoplasm Proteins , Proteoglycans , Vascular Endothelial Growth Factor A , Humans , Adrenal Cortex Neoplasms/metabolism , Adrenal Cortex Neoplasms/pathology , Adrenal Cortex Neoplasms/genetics , Male , Neoplasm Proteins/metabolism , Neoplasm Proteins/biosynthesis , Female , Proteoglycans/metabolism , Proteoglycans/genetics , Middle Aged , Vascular Endothelial Growth Factor A/metabolism , Adult , Prognosis , Adrenocortical Adenoma/metabolism , Adrenocortical Adenoma/pathology , Adrenocortical Adenoma/genetics , Adrenocortical Carcinoma/metabolism , Adrenocortical Carcinoma/pathology , Aged , Adrenal Cortex/metabolism , Adrenal Cortex/pathology , Young Adult
7.
BMJ Case Rep ; 17(6)2024 Jun 08.
Article in English | MEDLINE | ID: mdl-38851224

ABSTRACT

Adrenocortical tumours are rare in children and account for only 0.3%-0.4% of all neoplasms in childhood. They present with variable signs and symptoms, depending on the type of hormonal hypersecretion. The majority of the adrenocortical tumours in children are functional (90%) and malignant (88%). Here, we describe a functional plurihormonal oncocytic adrenal cortical adenoma in a young girl, that mimicked a malignant adrenal lesion, clinically as well as on imaging and biochemical features. This report bears the objective of being aware of the atypical biochemical as well as imaging characteristics of oncocytic adrenal tumours.


Subject(s)
Adrenal Cortex Neoplasms , Adrenocortical Adenoma , Female , Humans , Adenoma, Oxyphilic/pathology , Adenoma, Oxyphilic/diagnosis , Adenoma, Oxyphilic/diagnostic imaging , Adenoma, Oxyphilic/surgery , Adrenal Cortex Neoplasms/diagnosis , Adrenal Cortex Neoplasms/surgery , Adrenal Cortex Neoplasms/diagnostic imaging , Adrenal Cortex Neoplasms/pathology , Adrenocortical Adenoma/diagnosis , Adrenocortical Adenoma/surgery , Adrenocortical Adenoma/diagnostic imaging , Adrenocortical Adenoma/pathology , Diagnosis, Differential , Tomography, X-Ray Computed , Adolescent
8.
J Med Case Rep ; 18(1): 276, 2024 Jun 12.
Article in English | MEDLINE | ID: mdl-38863038

ABSTRACT

BACKGROUND: Currently, there is a scarcity of cases and diagnostic data regarding ectopic adrenocortical adenomas, particularly in relation to their impact on gonadal function and localization diagnostic techniques. We report a typical case of ectopic adrenocortical adenomas and the data of treatment follow-up, and review the literature of 31 available cases of ectopic adrenocortical adenomas. CASE PRESENTATION: A 27-year-old Chinese female patient was admitted to our hospital for hypertension, hyperglycaemia and primary amenorrhea. The patient was functionally diagnosed with ACTH-independent CS and hypogonadotropic hypogonadism. Radiological evaluations, including Computed Tomography (CT) and functional imaging, identified a mass at the left renal hilum. Histological assessments post-surgical excision confirmed the mass to be an ectopic adrenocortical adenoma. A subsequent 3-month follow-up showed no signs of disease recurrence, a swift recovery of the cortisol axis was observed, with a partial recuperation of the gonadal axis. REVIEW: Our literature review shows that the most common ectopic areas of cortisol adenomas are renal hilum and hepatic region. The most positive biomarker is Melan A, and only a few cases have been diagnosed with functional localization. CONCLUSION: Ectopic adrenocortical adenomas may be asymptomatic in the early stage and can impact gonadal function. Physicians who treat hypogonadism must be aware of the need to test cortisol levels and perform functional localization in patients with lumps present.


Subject(s)
Adrenal Cortex Neoplasms , Adrenocortical Adenoma , Hypogonadism , Humans , Female , Adult , Adrenocortical Adenoma/surgery , Adrenocortical Adenoma/pathology , Adrenocortical Adenoma/complications , Adrenal Cortex Neoplasms/surgery , Adrenal Cortex Neoplasms/pathology , Adrenal Cortex Neoplasms/diagnostic imaging , Tomography, X-Ray Computed , Hydrocortisone
9.
Endocrine ; 85(3): 1387-1397, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38884928

ABSTRACT

OBJECTIVE: To develop and validate a nomogram combining radiomics and pathology features to distinguish between aldosterone-producing adenomas (APAs) and nonfunctional adrenal adenomas (NF-AAs). METHODS: Consecutive patients diagnosed with adrenal adenomas via computed tomography (CT) or pathologic analysis between January 2011 and November 2022 were eligible for inclusion in this retrospective study. CT images and hematoxylin & eosin-stained slides were used for annotation and feature extraction. The selected radiomics and pathology features were used to develop a risk model using various machine learning models, and the area under the receiver operating characteristic curve (AUC) was determined to evaluate diagnostic performance. The predicted results from radiomics and pathology features were combined and visualized using a nomogram. RESULTS: A total of 211 patients (APAs, n = 59; NF-AAs, n = 152) were included in this study, with patients randomly divided into either the training set or the testing set at a ratio of 8:2. The ExtraTrees model yielded a sensitivity of 0.818, a specificity of 0.733, and an accuracy of 0.756 (AUC = 0.817; 95% confidence interval [CI]: 0.675-0.958) in the radiomics testing set and a sensitivity of 0.999, a specificity of 0.842, and an accuracy of 0.867 (AUC = 0.905, 95% CI: 0.792-1.000) in the pathology testing set. A nomogram combining radiomics and pathology features demonstrated a strong performance (AUC = 0.912; 95% CI: 0.807-1.000). CONCLUSION: A nomogram combining radiomics and pathology features demonstrated strong predictive accuracy and discrimination capability. This model may help clinicians to distinguish between APAs and NF-AAs.


Subject(s)
Adrenal Gland Neoplasms , Aldosterone , Humans , Female , Middle Aged , Male , Retrospective Studies , Adult , Aldosterone/metabolism , Aldosterone/blood , Diagnosis, Differential , Adrenal Gland Neoplasms/diagnostic imaging , Adrenal Gland Neoplasms/metabolism , Adrenal Gland Neoplasms/pathology , Aged , Tomography, X-Ray Computed , Adrenocortical Adenoma/diagnostic imaging , Adrenocortical Adenoma/metabolism , Adrenocortical Adenoma/pathology , Nomograms , Adenoma/diagnostic imaging , Adenoma/pathology , Adenoma/metabolism , Adrenal Cortex Neoplasms/diagnostic imaging , Adrenal Cortex Neoplasms/metabolism , Adrenal Cortex Neoplasms/pathology , Sensitivity and Specificity , Multimodal Imaging/methods
10.
Eur J Endocrinol ; 191(1): 47-54, 2024 Jul 02.
Article in English | MEDLINE | ID: mdl-38941271

ABSTRACT

OBJECTIVE: The aim of this study is to assess whether clinical and imaging characteristics are associated with the hormonal subtype, growth, and adrenalectomy for incidental adrenal cortical adenomas (ACAs). DESIGN: This is a single-center cohort study. METHODS: Consecutive adult patients with incidental ACA were diagnosed between 2000 and 2016. RESULTS: Of the 1516 patients with incidental ACA (median age 59 years, 62% women), 699 (46%) had nonfunctioning adenomas (NFAs), 482 (31%) had mild autonomous cortisol secretion (MACS), 62 (4%) had primary aldosteronism (PA), 39 (3%) had Cushing syndrome, 18 (1%) had PA and MACS, and 226 (15%) had incomplete work-up. Age, sex, tumor size, and tumor laterality, but not unenhanced computed tomography Hounsfield units (HU), were associated with hormonal subtypes. In a multivariable analysis, ≥1 cm growth was associated with younger age (odds ratio [OR] = 0.8 per 5-year increase, P = .0047) and longer imaging follow-up (OR = 1.2 per year, P < .0001). Adrenalectomy was performed in 355 (23%) patients, including 38% of MACS and 15% of NFA. Adrenalectomy for NFA and MACS was more common in younger patients (OR = 0.79 per 5-year increase, P = .002), larger initial tumor size (OR = 2.3 per 1 cm increase, P < .0001), ≥1 cm growth (OR = 15.3, P < .0001), and higher postdexamethasone cortisol (OR = 6.6 for >5 vs <1.8 µg/dL, P = .002). CONCLUSIONS: Age, sex, tumor size, and laterality were associated with ACA hormonal subtype and can guide diagnosis and management. Tumor growth was more common with younger age and longer follow-up. Unenhanced HU did not predict hormonal subtype or growth. Adrenalectomy for MACS and NFA was mainly performed in younger patients with larger tumor size, growth, and elevated postdexamethasone cortisol.


Subject(s)
Adrenal Cortex Neoplasms , Adrenalectomy , Adrenocortical Adenoma , Incidental Findings , Humans , Female , Male , Middle Aged , Adrenocortical Adenoma/surgery , Adrenocortical Adenoma/diagnostic imaging , Adrenocortical Adenoma/pathology , Retrospective Studies , Adrenal Cortex Neoplasms/surgery , Adrenal Cortex Neoplasms/diagnostic imaging , Adrenal Cortex Neoplasms/pathology , Aged , Adult , Cohort Studies , Hydrocortisone/blood , Cushing Syndrome/surgery , Cushing Syndrome/diagnostic imaging , Tomography, X-Ray Computed , Hyperaldosteronism/surgery , Hyperaldosteronism/diagnostic imaging
11.
Diagn Pathol ; 19(1): 71, 2024 May 27.
Article in English | MEDLINE | ID: mdl-38802933

ABSTRACT

BACKGROUND: Current diagnostic criteria of adrenocortical neoplasms are mostly based on morphology. The utility of immunohistochemistry (IHC) and histochemistry is limited. MATERIALS AND METHODS: To evaluate the diagnostic and prognostic utility of clinicopathological features, morphology, ancillary biomarkers, and reticular histochemistry in adrenocortical neoplasms. We examined 28 adrenocortical carcinomas (ACCs) and 50 adrenocortical adenomas (ACAs) obtained from pathology archives. Clinical data were retrieved from medical records. Two pathologists independently assessed hematoxylin and eosin-stained slides, employing modified Weiss criteria for all tumors and Lin-Weiss-Bisceglia criteria for oncocytic variants. Immunohistochemical markers (Calretinin, alpha-inhibin, MelanA, SF-1, Ki-67, PHH3, IGF-2, ß-catenin, P53, CYP11B1, CYP11B2, MLH1, MSH2, MSH6, PMS2, EPCAM) and Gomori's Silver histochemistry were applied. Statistical analysis utilized SPSS Statistics 26. RESULTS: ACCs exhibited larger tumor sizes (P<0.001) and symptomatic presentations (P = 0.031) compared to ACAs. Parameters of modified Weiss criteria and angioinvasion demonstrated diagnostic value for ACCs. Six immunohistochemical antibodies((MelanA, Ki-67, IGF-2, ß-catenin, P53 and CYP11B1) and reticulin framework alterations showed diagnostic value. Notably, Ki-67 and reticulin staining were most recommended. Evident reticulin staining was frequently present in ACCs (P<0.001). Ki-67 was significantly higher in ACCs (P<0.001). Twenty-one conventional and seven oncocytic entities showed different necrosis frequencies. Symptoms and Ki-67 index ≥ 30% were prognostic for ACCs, correlating with shorter survival. CONCLUSIONS: This study emphasizes the diagnostic value of reticulin framework alterations and a high Ki-67 index. Markers such as CYP11B1, IGF2, P53, ß-catenin and MelanA also contribute to the diagnosis of ACCs. Symptoms and Ki-67 index ≥ 30% predict shorter survival. These findings encourges the use of ancillary markers such as reticulin histochemistry and Ki-67 in the workup of evaluations of adrenocortical neoplasms.


Subject(s)
Adrenal Cortex Neoplasms , Adrenocortical Carcinoma , Biomarkers, Tumor , Immunohistochemistry , Humans , Adrenal Cortex Neoplasms/pathology , Adrenal Cortex Neoplasms/diagnosis , Adrenocortical Carcinoma/pathology , Adrenocortical Carcinoma/diagnosis , Adrenocortical Carcinoma/metabolism , Male , Female , Biomarkers, Tumor/analysis , Middle Aged , Adult , Prognosis , Aged , Young Adult , Adolescent , Adrenocortical Adenoma/pathology , Adrenocortical Adenoma/diagnosis , Adrenocortical Adenoma/metabolism , Child
12.
Ann Surg Oncol ; 31(8): 5122-5127, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38802716

ABSTRACT

BACKGROUND: Many adrenal tumors are deemed radiologically indeterminate and surgically removed. Adrenal tissue, like parathyroid glands, exhibits near-infrared autofluorescence (NIRAF) properties. This study was designed to investigate the potential of NIRAF to differentiate benign versus malignant adrenal tumors. METHODS: Patients undergoing adrenalectomy between October 2021 and May 2023 were prospectively studied. Adrenalectomy specimens were inspected with NIRAF imaging. Specimen autofluorescence (AF) characteristics were recorded. Comparisons were made between different tumor types and a logistic regression model was constructed to differentiate benign versus malignant tumors. A receiver operating characteristic curve was used to identify an optimal AF threshold differentiating benign versus malignant tumors. RESULTS: A total of 108 adrenal specimens were examined: adrenocortical adenomas/other benign lesions (n = 72), pheochromocytomas (n = 18), adrenocortical neoplasms of uncertain behavior (n = 4), and malignant tumors (n = 14). A significant difference in normalized AF intensity was identified when comparing adrenocortical adenomas (3.08 times background) with pheochromocytomas (1.95, p = 0.001) and malignant tumors (1.11, p < 0.0001). The Area Under the Curve differentiating benign vs malignant tumors was 0.87, with an optimal normalized AF threshold at 1.93. CONCLUSIONS: Different adrenal pathologies exhibit diverse AF properties. These findings suggest a potential intraoperative utility of NIRAF in predicting benign versus malignant nature for radiologically indeterminate adrenal tumors.


Subject(s)
Adrenal Gland Neoplasms , Optical Imaging , Pheochromocytoma , Humans , Adrenal Gland Neoplasms/pathology , Adrenal Gland Neoplasms/surgery , Adrenal Gland Neoplasms/diagnostic imaging , Female , Male , Middle Aged , Pheochromocytoma/pathology , Pheochromocytoma/surgery , Pheochromocytoma/diagnostic imaging , Prospective Studies , Optical Imaging/methods , Adrenalectomy , Adult , ROC Curve , Adrenocortical Adenoma/pathology , Adrenocortical Adenoma/surgery , Adrenocortical Adenoma/diagnostic imaging , Aged , Diagnosis, Differential , Follow-Up Studies , Prognosis , Adrenal Cortex Neoplasms/pathology , Adrenal Cortex Neoplasms/surgery , Adrenal Cortex Neoplasms/diagnostic imaging , Spectroscopy, Near-Infrared/methods
13.
High Blood Press Cardiovasc Prev ; 31(3): 299-308, 2024 May.
Article in English | MEDLINE | ID: mdl-38763953

ABSTRACT

INTRODUCTION: The fluctuations of the intracellular Ca2+ concentration ([Ca2+]i) are key physiological signals for cell function under normal conditions and can undergo profound alterations in disease states, as high blood pressure due to endocrine disorders like primary aldosteronism (PA). However, when assessing such fluctuations several parameters in the Ca2+ signal dynamics need to be considered, which renders their assessment challenging. AIM: Aim to develop an observer-independent custom-made pipeline to analyze Ca2+ dynamics in terms of frequency and peak parameters, as amplitude, full width at half maximum (FWHM) and area under the curve (AUC). METHODS: We applied a custom-made methodology to aldosterone-producing adenoma (APA) and APA adjacent cells (AAC) and found this pipeline to be suitable for monitoring and processing a wide-range of [Ca2+]i events in these cell types delivering reproducible results. CONCLUSION: The designed pipeline can provide a useful tool for [Ca2+]i signal analysis that allows comparisons of Ca2+ dynamics not only in PA, but in other cell phenotypes that are relevant for the regulation of blood pressure.


Subject(s)
Adrenal Cortex Neoplasms , Adrenal Cortex , Adrenocortical Adenoma , Calcium Signaling , Hyperaldosteronism , Humans , Adrenal Cortex Neoplasms/metabolism , Adrenal Cortex Neoplasms/pathology , Hyperaldosteronism/metabolism , Adrenocortical Adenoma/metabolism , Adrenocortical Adenoma/pathology , Adrenal Cortex/metabolism , Aldosterone/metabolism , Calcium/metabolism , Reproducibility of Results , Cells, Cultured , Time Factors
14.
EBioMedicine ; 103: 105087, 2024 May.
Article in English | MEDLINE | ID: mdl-38570222

ABSTRACT

BACKGROUND: The human adrenal cortex consists of three functionally and structurally distinct layers; zona glomerulosa, zona fasciculata (zF), and zona reticularis (zR), and produces adrenal steroid hormones in a layer-specific manner; aldosterone, cortisol, and adrenal androgens, respectively. Cortisol-producing adenomas (CPAs) occur mostly as a result of somatic mutations associated with the protein kinase A pathway. However, how CPAs develop after adrenocortical cells acquire genetic mutations, remains poorly understood. METHODS: We conducted integrated approaches combining the detailed histopathologic studies with genetic, RNA-sequencing, and spatially resolved transcriptome (SRT) analyses for the adrenal cortices adjacent to human adrenocortical tumours. FINDINGS: Histopathological analysis revealed an adrenocortical nodular structure that exhibits the two-layered zF- and zR-like structure. The nodular structures harbour GNAS somatic mutations, known as a driver mutation of CPAs, and confer cell proliferative and autonomous steroidogenic capacities, which we termed steroids-producing nodules (SPNs). RNA-sequencing coupled with SRT analysis suggests that the expansion of the zF-like structure contributes to the formation of CPAs, whereas the zR-like structure is characterised by a macrophage-mediated immune response. INTERPRETATION: We postulate that CPAs arise from a precursor lesion, SPNs, where two distinct cell populations might contribute differently to adrenocortical tumorigenesis. Our data also provide clues to the molecular mechanisms underlying the layered structures of human adrenocortical tissues. FUNDING: KAKENHI, The Uehara Memorial Foundation, Daiwa Securities Health Foundation, Kaibara Morikazu Medical Science Promotion Foundation, Secom Science and Technology Foundation, ONO Medical Research Foundation, and Japan Foundation for Applied Enzymology.


Subject(s)
Adrenal Cortex Neoplasms , Hydrocortisone , Humans , Hydrocortisone/metabolism , Adrenal Cortex Neoplasms/genetics , Adrenal Cortex Neoplasms/metabolism , Adrenal Cortex Neoplasms/pathology , Mutation , Adrenocortical Adenoma/genetics , Adrenocortical Adenoma/metabolism , Adrenocortical Adenoma/pathology , Adrenal Cortex/metabolism , Adrenal Cortex/pathology , Gene Expression Profiling , Transcriptome , Steroids/biosynthesis , Steroids/metabolism , Adenoma/pathology , Adenoma/metabolism , Adenoma/genetics , Male , Female , Middle Aged
16.
Ann Ital Chir ; 95(1): 13-16, 2024.
Article in English | MEDLINE | ID: mdl-38469607

ABSTRACT

AIM: We present a case of adrenocortical adenoma originating from the adrenohepatic fusion (AHF) region, accompanied by advanced hepatosteatosis in the liver tissue, and discuss its distinction from hepatocellular carcinoma.  Case Experience: A 68-year-old male patient was admitted to the hospital following a fall from a height. He was referred to our hospital after an incidental discovery of a liver mass during an abdominal ultrasound examination. Subsequently, magnetic resonance imaging (MRI) imaging was conducted, followed by segmental liver resection with right adrenalectomy, and histological analysis of a biopsy from the lesion.  Results: Upon histologic examination, the case was determined to be an adrenocortical adenoma originating from the AHF.  Discussion: Adrenohepatic fusion (AHF) denotes the histological amalgamation of cells from the right adrenal cortex and right hepatic parenchyma. Only a limited number of cases of neoplasia originating from this region have been documented. These rare instances often present a diagnostic challenge, with preoperative imaging frequently misidentifying them as primary malignancies of either hepatic or adrenal origin, potentially leading to unnecessary extensive resections. The integration of immunohistochemical staining alongside clinical and radiological data proves helpful for accurately diagnosing this condition.  Conclusion: Awareness among clinicians, radiologists, and pathologists regarding the tumors that may arise from this region can mitigate the risk of performing extensive resections unnecessarily.


Subject(s)
Adrenal Cortex Neoplasms , Adrenocortical Adenoma , Carcinoma, Hepatocellular , Liver Neoplasms , Male , Humans , Aged , Adrenocortical Adenoma/diagnostic imaging , Adrenocortical Adenoma/surgery , Adrenocortical Adenoma/pathology , Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/surgery , Carcinoma, Hepatocellular/pathology , Adrenal Cortex Neoplasms/diagnostic imaging , Adrenal Cortex Neoplasms/surgery , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/surgery
18.
Clin Chim Acta ; 553: 117749, 2024 Jan 15.
Article in English | MEDLINE | ID: mdl-38169194

ABSTRACT

The measurement of steroid hormones in blood and urine, which reflects steroid biosynthesis and metabolism, has been recognized as a valuable tool for identifying and distinguishing steroidogenic disorders. The application of mass spectrometry enables the reliable and simultaneous analysis of large panels of steroids, ushering in a new era for diagnosing adrenal diseases. However, the interpretation of complex hormone results necessitates the expertise and experience of skilled clinicians. In this scenario, machine learning techniques are gaining worldwide attention within healthcare fields. The clinical values of combining mass spectrometry-based steroid profiles analysis with machine learning models, also known as steroid metabolomics, have been investigated for identifying and discriminating adrenal disorders such as adrenocortical carcinomas, adrenocortical adenomas, and congenital adrenal hyperplasia. This promising approach is expected to lead to enhanced clinical decision-making in the field of adrenal diseases. This review will focus on the clinical performances of steroid profiling, which is measured using mass spectrometry and analyzed by machine learning techniques, in the realm of decision-making for adrenal diseases.


Subject(s)
Adrenal Cortex Neoplasms , Adrenal Gland Diseases , Adrenocortical Adenoma , Adrenocortical Carcinoma , Humans , Adrenal Gland Diseases/diagnosis , Adrenal Gland Diseases/metabolism , Adrenocortical Adenoma/diagnosis , Adrenocortical Adenoma/pathology , Adrenocortical Carcinoma/diagnosis , Steroids/metabolism , Adrenal Cortex Neoplasms/diagnosis
19.
Hypertension ; 81(2): 361-371, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38095094

ABSTRACT

BACKGROUND: Recent advances in omics techniques have allowed detailed genetic characterization of aldosterone-producing adenoma (APA). The pathogenesis of APA is characterized by tumorigenesis-associated aldosterone synthesis. The pathophysiological intricacies of APAs have not yet been elucidated at the level of individual cells. Therefore, a single-cell level analysis is speculated to be valuable in studying the differentiation process of APA. METHODS: We conducted single-nucleus RNA sequencing of APAs with KCNJ5 mutation and nonfunctional adenomas obtained from 3 and 2 patients, respectively. RESULTS: The single-nucleus RNA sequencing revealed the intratumoral heterogeneity of APA and identified cell populations consisting of a shared cluster of nonfunctional adenoma and APA. In addition, we extracted 2 cell fates in APA and obtained a cell population specialized in aldosterone synthesis. Genes related to ribosomes and neurodegenerative diseases were upregulated in 1 of these fates, whereas those related to the regulation of glycolysis were upregulated in the other fate. Furthermore, the total RNA reads in the nucleus were higher in hormonally activated clusters, indicating a marked activation of transcription per cell. CONCLUSIONS: The single-nucleus RNA sequencing revealed intratumoral heterogeneity of APA with KCNJ5 mutation. The observation of 2 cell fates in KCNJ5-mutated APAs provides the postulation that a heterogeneous process of cellular differentiation was implicated in the pathophysiological mechanisms underlying APA tumors.


Subject(s)
Adenoma , Adrenal Cortex Neoplasms , Adrenocortical Adenoma , Hyperaldosteronism , Humans , Aldosterone , Adrenocortical Adenoma/genetics , Adrenocortical Adenoma/pathology , Adenoma/genetics , Adenoma/pathology , G Protein-Coupled Inwardly-Rectifying Potassium Channels/genetics , Mutation , Adrenal Cortex Neoplasms/genetics , Hyperaldosteronism/genetics
20.
J Clin Endocrinol Metab ; 109(8): e1582-e1592, 2024 Jul 12.
Article in English | MEDLINE | ID: mdl-38127970

ABSTRACT

CONTEXT: Clinical implications of unilateral primary aldosteronism (PA) histopathology remain to be determined in various ethnic populations. OBJECTIVE: We examined the histopathology of unilateral PA using CYP11B2 immunostaining in relation to clinical phenotypes and postsurgical outcomes. METHODS: Patients consecutively operated for unilateral PA from 2010 to 2020 at 3 tertiary hospitals in South Korea were retrospectively enrolled. Adrenals with solitary aldosterone-producing adenomas and/or dominant aldosterone-producing nodules were classified as the classical and the others as the nonclassical groups. The classical group was subdivided into mixed or solitary group according to whether other aldosterone-producing lesions coexist or not. RESULTS: Of the 240 cases, 124 were solitary, 86 mixed, and 30 nonclassical. Baseline serum potassium concentration was lower in the solitary group than the mixed or nonclassical group. Plasma aldosterone concentration after saline loading was the highest in the solitary group (median 31.65 ng/dL), followed by the mixed group (median 25.40 ng/dL), and the lowest in the nonclassical group (median 14.20 ng/dL). Solitary and mixed groups showed higher lateralization indices and lower contralateral indices than the nonclassical group. The contralateral index was lower in the solitary group than the mixed group. At 6 to 12 months after adrenalectomy, fewer antihypertensive medications were required for the solitary and mixed groups than the nonclassical group. CONCLUSION: The solitary group, followed by the mixed group, was associated with more severe hyperaldosteronism and more suppressed aldosterone production from the contralateral side than the nonclassical group. Histopathologic phenotypes were related to the clinical manifestations and may suggest postoperative prognosis.


Subject(s)
Adrenalectomy , Aldosterone , Hyperaldosteronism , Phenotype , Humans , Hyperaldosteronism/surgery , Hyperaldosteronism/pathology , Hyperaldosteronism/blood , Female , Male , Middle Aged , Retrospective Studies , Adult , Aldosterone/blood , Treatment Outcome , Republic of Korea/epidemiology , Adrenal Cortex Neoplasms/surgery , Adrenal Cortex Neoplasms/pathology , Adrenal Cortex Neoplasms/complications , Cytochrome P-450 CYP11B2 , Prognosis , Aged , Adrenocortical Adenoma/surgery , Adrenocortical Adenoma/pathology , Adrenocortical Adenoma/complications , Adrenocortical Adenoma/blood
SELECTION OF CITATIONS
SEARCH DETAIL